MX2022006737A - Analogos peptidicos del peptido insulinotropico dependiente de glucosa (gip) optimizados. - Google Patents

Analogos peptidicos del peptido insulinotropico dependiente de glucosa (gip) optimizados.

Info

Publication number
MX2022006737A
MX2022006737A MX2022006737A MX2022006737A MX2022006737A MX 2022006737 A MX2022006737 A MX 2022006737A MX 2022006737 A MX2022006737 A MX 2022006737A MX 2022006737 A MX2022006737 A MX 2022006737A MX 2022006737 A MX2022006737 A MX 2022006737A
Authority
MX
Mexico
Prior art keywords
peptide
gip
dependent insulinotropic
glucose
optimized
Prior art date
Application number
MX2022006737A
Other languages
English (en)
Spanish (es)
Inventor
Alexander Hovard Sparre-Ulrich
Ditte Riber
Mette Marie Rosenkilde
Samra Joke Sanni
Original Assignee
Antag Therapeutics Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2019/083506 external-priority patent/WO2020115048A1/en
Application filed by Antag Therapeutics Aps filed Critical Antag Therapeutics Aps
Publication of MX2022006737A publication Critical patent/MX2022006737A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/645—Secretins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
MX2022006737A 2019-12-03 2020-12-03 Analogos peptidicos del peptido insulinotropico dependiente de glucosa (gip) optimizados. MX2022006737A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
PCT/EP2019/083506 WO2020115048A1 (en) 2018-12-03 2019-12-03 Modified gip peptide analogues
EP20179259 2020-06-10
PCT/EP2020/084487 WO2021110845A1 (en) 2019-12-03 2020-12-03 Optimized gip peptide analogues

Publications (1)

Publication Number Publication Date
MX2022006737A true MX2022006737A (es) 2022-06-14

Family

ID=71083547

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022006737A MX2022006737A (es) 2019-12-03 2020-12-03 Analogos peptidicos del peptido insulinotropico dependiente de glucosa (gip) optimizados.

Country Status (9)

Country Link
US (1) US20250346647A2 (https=)
EP (1) EP4069719A1 (https=)
JP (2) JP7788376B2 (https=)
KR (1) KR20220108064A (https=)
AU (1) AU2020398675A1 (https=)
CA (1) CA3157387A1 (https=)
IL (1) IL293249A (https=)
MX (1) MX2022006737A (https=)
WO (1) WO2021110845A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20240021212A (ko) * 2021-06-10 2024-02-16 안타그 테라퓨틱스 에이피에스 비만 및 비만-관련 장애의 치료
WO2023139106A2 (en) * 2022-01-18 2023-07-27 Novo Nordisk A/S Long-acting gipr antagonists
UY40349A (es) * 2022-07-13 2024-01-31 Hangzhou Zhongmeihuadong Pharmaceutical Co Ltd Agonista dual de glp-1/gip, método de preparación y uso del mismo
WO2025259957A1 (en) * 2024-06-14 2025-12-18 Eli Lilly And Company Compositions and methods for improving insulin sensitivity

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0606992A2 (pt) * 2005-02-11 2009-07-28 Amylin Pharmaceuticals Inc análogo e polipeptìdeos hìbridos de gip com propriedades selecionáveis
US8263545B2 (en) * 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
AU2007284365A1 (en) * 2006-08-17 2008-02-21 Amylin Pharmaceuticals, Inc. DPP-IV resistant GIP hybrid polypeptides with selectable properties
WO2010016936A1 (en) * 2008-08-07 2010-02-11 Ipsen Pharma S.A.S. Pharmaceutical compositions of analogues of glucose-dependent insulinotropic polypeptide
KR101417873B1 (ko) * 2008-08-07 2014-07-09 입센 파마 에스.에이.에스 포도당 의존적인 인슐린 분비 자극성 폴리펩타이드의 유사체
JP2011530507A (ja) * 2008-08-07 2011-12-22 イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ グルコース依存性インスリン分泌刺激ポリペプチドアナログ
JP6228187B2 (ja) * 2012-05-03 2017-11-08 ジーランド ファーマ アクティーゼルスカブ Ｇｉｐ−ｇｌｐ−１デュアルアゴニスト化合物及び方法
US10968266B2 (en) * 2014-09-05 2021-04-06 University Of Copenhagen GIP peptide analogues
PL3630806T3 (pl) * 2017-05-31 2024-05-13 The University Of Copenhagen Analogi peptydów gip o długotrwałym działaniu
TWI912614B (zh) * 2017-12-21 2026-01-21 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
CN121449721A (zh) * 2018-12-03 2026-02-03 安泰博医药 经修饰的gip肽类似物

Also Published As

Publication number Publication date
WO2021110845A1 (en) 2021-06-10
EP4069719A1 (en) 2022-10-12
JP2023505441A (ja) 2023-02-09
CA3157387A1 (en) 2021-06-10
KR20220108064A (ko) 2022-08-02
US20250346647A2 (en) 2025-11-13
IL293249A (en) 2022-07-01
JP2025172864A (ja) 2025-11-26
JP7788376B2 (ja) 2025-12-18
AU2020398675A1 (en) 2022-05-26
CN114761420A (zh) 2022-07-15
US20230416330A1 (en) 2023-12-28

Similar Documents

Publication Publication Date Title
MX2021006505A (es) Analogos peptidicos del peptido insulinotropico dependiente de glucosa (gip) modificados.
MX2022006737A (es) Analogos peptidicos del peptido insulinotropico dependiente de glucosa (gip) optimizados.
CY1125359T1 (el) Νεα υποκατεστημενα με 6-6 δικυκλικο αρωματικο δακτυλιο νουκλεοσιδικα αναλογα για χρηση ως αναστολεις prmt5
PE20210162A1 (es) Analogos de incretina y sus usos
CL2020002034A1 (es) Agonista triple de receptores de glucagón/glp-1/gip. (divisional solicitud 201801776)
CY1121032T1 (el) Παραγωγα εξενδινης-4 ως επιλεκτικοι αγωνιστες υποδοχεα γλυκαγονης
MX2020001525A (es) Composiciones de peptido similar al glucagon tipo 1 (glp-1) y sus usos.
CL2019002297A1 (es) Inhibidores de mnk sustituidos con piperidina y métodos relacionados con los mismos.
MX2017015105A (es) Compuestos del peptido yy (pyy) selectivos y sus usos.
MX2017016482A (es) Lactamas biciclicas y metodos de uso de las mismas.
DK4122954T3 (da) Novel GLP-1-analoger
MX390698B (es) Antagonistas del receptor 7/8 tipo toll (tlr7/8) y uso de los mismos.
EA201990851A1 (ru) Новые аналоги карбануклеозида, замещенные моноциклической и бициклической кольцевой системой, для применения в качестве ингибиторов prmt5
MX2016011632A (es) Derivados de azaspiro como antagonistas de trpm8.
BR112019025195A8 (pt) análogos do peptídeo gip de ação prolongada
MX2017004559A (es) Receptores de celulas t.
CL2018003319A1 (es) Compuestos de mic-1 y usos de estos.
NZ743488A (en) Controlled-release cnp agonists with low initial npr-b activity
EA201791896A1 (ru) Дезацетокситубулизин н и его аналоги
CL2018003121A1 (es) Inhibidores del potenciador del homólogo zeste 2.
CU20210099A7 (es) Anticuerpos de receptor de péptido natriurético 1
IL285547A (en) Long-acting glp-2 analogs
EA202091095A1 (ru) Пероральная доставка пептидных аналогов glp-1
CL2022001227A1 (es) Agonistas del receptor npy2
DK3886813T3 (da) Farmaceutiske formuleringer af cyclosporinanaloger